Researchers at CSU are conducting lab-based research on the impact of cannabidiol (CBD) against canine glioma cells, or brain and spinal cancer. The research began in early 2019.
CBD has been shown to possess anti-tumor effects in human and rodent gliomas, according to the release, and several studies demonstrate a similarity in canine and human gliomas. The initial phase of research is almost complete, and the team at CSU hopes to publish study results within the next year.
Related: Healthy, Happy Pets = Happy Customers! KeHE Lists Top 5 2020 Trends FDA Discusses Legality CBD at CRN Conference
Extract Labs is supplying all of the CBD isolate and oils being used for research in this study. Consumers who purchase Extract Labs products on the company’s website have the opportunity to donate towards the costs of funding the CSU study.Craig Henderson, Founder and CEO of Extract Labs, said in the release: “We are proud to be one of the few CBD companies in America currently funding canine cancer research through a university that is world-renowned for its medical care and research”
Dr. Stephanie McGrath, a neurologist at CSU’s veterinary teaching hospital, added: “While this research is in very early stages, we look forward to learning more about the potential impact that CBD has on canine glioma cells.”
